Business
NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025
SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer’s disease during a poster presentation at the upcoming Alzheimer’s Associ
About this update from Nkgen Biotech Inc.
[{"type":"image","alt":"NKGen Biotech, Inc.","displaySize":"","headline":null,"caption":"NKGen Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XRU5Bz8FlnWhn7nRqZ2pow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6148ed3e2e28e6c539be48d0406ad510","width":300,"height":88}},"lazy":false},{"type":"text","content":"SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present on the mechanism of action for troculeucel, enhanced non-genetically modified NK cell therapy, in Alzheimer’s disease during a poster presentation at the upcoming Alzheimer’s Association International Conference 2025 (“AAIC 2025”) to be held in Toronto, Canada and online from July 27-31, 2025.","length":613,"tagName":"p"},{"type":"text","content":"Presentation details are as follows:","length":36,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:15%;width:15%;min-width:15%;vertical-align:bottom;","val":[{"type":"text","content":"Poster Title:","length":13,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;vertical-align:bottom;","val":[{"type":"text","content":"Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer’s Disease Confirmed by Corresponding Phase I Biomarker Data.","length":183,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"max-width:15%;width:15%;min-width:15%;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;vertical-align:bottom;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Presenting Author:","length":18,"tagName":"p","attribs":{}}]},{"style":"vertical-align:bottom;","val":[{"type":"text","content":"Paul Y. Song, M.D.","length":18,"tagNam...